PUBLIC COMPANY
save$RVMDRevolution Medicines, Inc.
$RVMD212.00+4.07%Redwood City, CA, USupdated 8h ago
community read0 votes
pipeline
2
marketed
0
phase 3
1
catalysts ytd
4
approvals ytd
0
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Phase 21Phase 3
Upcoming
Recent(90d)
earnings (1)
Active trials
- phase3Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
- —Expanded Access Program for Daraxonrasib (RMC-6236) in Previously Treated Metastatic Pancreatic Adenocarcinoma
- phase3Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
- phase2Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
- phase1Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
- phase3Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
- phase2Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
- phase2Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors
Insider activity
source: SEC Form 4open-market buys + sells
- Apr 15, 26SELLGOLDSMITH MARK A· See Remarks−$18.01M↗
- Mar 25, 26SELLMancini Anthony· See Remarks−$2.01M↗
- Mar 25, 26SELLMancini Anthony· See Remarks−$1.06M↗
- Mar 25, 26SELLMancini Anthony· See Remarks−$295K↗
- Mar 25, 26SELLMancini Anthony· See Remarks−$168K↗
- Mar 25, 26SELLMancini Anthony· See Remarks−$39K↗
- Mar 19, 26SELLCislini Jeff· General Counsel−$113K↗
- Mar 17, 26SELLGOLDSMITH MARK A· See Remarks−$1.28M↗
- Mar 17, 26SELLHorn Margaret A· Chief Operating Officer−$456K↗
- Mar 17, 26SELLKelsey Stephen Michael· See Remarks−$428K↗
- Mar 17, 26SELLAnders Jack· Chief Financial Officer−$274K↗
- Mar 17, 26SELLWei Lin· Chief Medical Officer−$206K↗
- Mar 17, 26SELLWang Xiaolin· See Remarks−$200K↗
- Mar 17, 26SELLCislini Jeff· General Counsel−$179K↗
- Mar 2, 26SELLGOLDSMITH MARK A· See Remarks−$2.17M↗
- Mar 2, 26SELLGOLDSMITH MARK A· See Remarks−$365K↗
- Mar 2, 26SELLGOLDSMITH MARK A· See Remarks−$349K↗
- Mar 2, 26SELLGOLDSMITH MARK A· See Remarks−$213K↗
- Mar 2, 26SELLGOLDSMITH MARK A· See Remarks−$173K↗
- Mar 2, 26SELLGOLDSMITH MARK A· See Remarks−$87K↗
🐶 Hiring Signal
next earnings Nov 4, 2026
Where Revolution Medicines, Inc. is staffing up — a leading indicator of pipeline and commercial priorities.
therapeutic areaOncology 295CNS / Neuroscience 1
News
- Novo escalates legal fight with Lilly; J&J reinforces ‘dominance’ in multiple myelomaNovo is seeking an injunction that would halt allegedly “misleading” obesity drug ads. Elsewhere, the FDA began reviewing a highly anticipated medicine and a veteran investor landed at an AI startup.biopharma_dive · 24d ago
- BlossomHill eyes IPO as fertilizer to grow taller in crowded cancer fieldsAnother biotech is squeezing into the crowded IPO waiting room just in time for the weekend. BlossomHill Therapeutics, a San Diego-based oncology outfit focused on small molecules, has filed paperw…fiercebiotech · 1mo ago
- STAT+: J&J spends $1 billion to enter KRAS race for cancer treatmentsJohnson & Johnson said it will purchase the startup Firefly Bio for $1 billion in an effort to expand its work in the suddenly buzzy field of KRAS inhibitors.stat · 2mo ago
- STAT+: For pancreatic cancer patients, an exciting drug can feel out of reachFor pancreatic cancer patients, the surge in interest for an exciting new drug is leaving them fearful about when they might get the treatment or if there will be enough…stat · 2mo ago
- STAT+: Practice-changing results reported for Revolution Medicines pancreatic cancer drugMuch-awaited results at ASCO show that scientists have indeed found a way to drug a "greasy ball" involved in pancreatic cancer.stat · 2mo ago
- Cases and Conversations™: Next-Generation Pathology Advances and Considerations for Precision Care in Non–Small Cell Lung Canceronclive · 3mo ago
Data sources
last refreshed 21m ago
Found something off?
comments(0)
5-min edit window · permanent after that